To print: Select File and then Print from your browser's menu

Title: Capecitabine Shows Improved Safety Over 5-fluorouracil-based Adjuvant Treatment for Colon Cancer

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=14630678

Annals of Oncology 2003;14:1735-1743. "Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial"
12/04/2003 10:00:00 AM
By Mary Beth Nierengarten

For patients with metastatic colorectal cancer, oral capecitabine may be a more attractive first-line therapy over the current choice of 5-fluorouracil-leucovorin (5-FU/LV) based on its improved safety profile, reports a multinational study. Although adjuvant 5-FU/LV has improved outcomes for patients with Dukes' C colon (stage III) colon cancer and is considered standard treatment, it is often not used in community practice because of associated adverse effects and subsequent poor compliance. Along with a high activity profile, capecitabine has been shown to be well tolerated and convenient or patients with metastatic disease. To compare the efficacy and safety of capecitabine and 5-FU/LV for patients with Dukes' C colon cancer, W. Scheithauer, MD, Vienna University Medical School, Austria, and colleagues randomised 993 patients to 24 weeks of oral capecitabine (1250 mg/m[²), twice daily, days 1-14 every 21 days) and 974 patients to intravenous bolus 5-FU (425 mg/m²) with intravenous leucovorin (20 mg/m²), days 1-5, repeated every 28 days. For patients with moderate renal impairment, the starting dose of capecitabine was eventually reduced by 25%. The purpose of this study was to report the prospective results of a planned safety analysis at 19 months after study enrolment. Overall, patients receiving capecitabine experienced significantly less adverse events than those receiving 5-FU-LV, with less diarrhoea (46% vs. 64%), nausea/vomiting (36% vs. 51%), alopecia (6% vs. 22%), stomatitis (22% vs. 60%), and neutropenia (2% vs. 8%) (significance of P < .001 for all comparisons). Severe adverse events were also significantly reduced with capecitabine, including less grade 3 or 4 stomatitis (2% vs. 14%), grade 3 or 4 neutropenia (0.6% vs. 5%), and febrile neutropenia/sepsis (0.3% vs. 3%) (significance of P < .001 for all comparisons). Hand-foot syndrome was the only significantly increased adverse event associated with capecitabine (62% vs. 10%; P < .001). Tolerability of capecitabine was not dependent on age, with comparable early severe toxicities reported in patients 65 years or older or those younger than 65 (4.9% vs. 6.3%, respectively). In contrast, patients over 65 years old who were receiving 5-FU-LV reported higher incidence of early severe toxicities compared to younger patients (20% vs. 15%, respectively). Although the efficacy results of this trial will not expected until next year, the authors conclude that "from a safety perspective, capecitabine can replace 5-FU-LV as the standard adjuvant treatment for patients with colon cancer."

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=14630678

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.